Neoprobe 4th Quarter and Year-End 2009 Earnings Conference Call Invitation

Conference Call Scheduled for 11:00 AM ET, Thursday, March 4^th

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the fourth quarter and full year of 2009 on Wednesday, March 3, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community scheduled for the following morning, Thursday, March 4, 2010 at 11:00 AM ET.

Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a general business update and discuss the company's financial results for the fourth quarter and full year of 2009 during the conference call scheduled for 11:00 AM ET, Thursday, March 4, 2010. The conference call can be accessed as follows:

The Company also plans to hold a conference call in March to discuss the clinical and regulatory status of its Lymphoseek^® initiative. Recent weather conditions in the Washington, D.C. area resulted in the postponement of a scheduled end-of-Phase 3 meeting with FDA. The Company still believes it will be in a position to discuss the results of that meeting before the end of the first quarter.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe^® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek^® and RIGScan™ CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statementsThe words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof.Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings.The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Contacts:

Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
The Shoreham Group
Tim Ryan, 212-242-7777